

Global Checkpoint Inhibitor Refractory Cancer Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/GCD243FFB0ABEN.html>

Date: August 2024

Pages: 146

Price: US\$ 3,200.00 (Single User License)

ID: GCD243FFB0ABEN

Abstracts

Report Overview

This report provides a deep insight into the global Checkpoint Inhibitor Refractory Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Checkpoint Inhibitor Refractory Cancer Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Checkpoint Inhibitor Refractory Cancer market in any manner.

Global Checkpoint Inhibitor Refractory Cancer Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding

the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Bristol-Myers Squibb

AstraZeneca

Merck

Roche

Regeneron Pharmaceuticals

Bristol-Myers Squibb

Janssen Research and Development

4D pharma

4SC AG

OncoSec Medical

Mirati Therapeutics

Ascentage Pharma Group

ENB Therapeutics

Excicure

Eisai

Kartos Therapeutics

Exelixis

ImmunityBio

Market Segmentation (by Type)

PD-1 Inhibitors

PD-L1 Inhibitors

Market Segmentation (by Application)

Hodgkin Lymphoma

Kidney Cancer

Melanoma

Non-Small Cell Lung Cancer

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Checkpoint Inhibitor Refractory Cancer Market

Overview of the regional outlook of the Checkpoint Inhibitor Refractory Cancer Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the

region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Checkpoint Inhibitor Refractory Cancer Market and its likely evolution in the short to mid-

term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

- 1.1 Market Definition and Statistical Scope of Checkpoint Inhibitor Refractory Cancer
- 1.2 Key Market Segments
 - 1.2.1 Checkpoint Inhibitor Refractory Cancer Segment by Type
 - 1.2.2 Checkpoint Inhibitor Refractory Cancer Segment by Application
- 1.3 Methodology & Sources of Information
 - 1.3.1 Research Methodology
 - 1.3.2 Research Process
 - 1.3.3 Market Breakdown and Data Triangulation
 - 1.3.4 Base Year
 - 1.3.5 Report Assumptions & Caveats

2 CHECKPOINT INHIBITOR REFRACTORY CANCER MARKET OVERVIEW

- 2.1 Global Market Overview
 - 2.1.1 Global Checkpoint Inhibitor Refractory Cancer Market Size (M USD) Estimates and Forecasts (2019-2030)
 - 2.1.2 Global Checkpoint Inhibitor Refractory Cancer Sales Estimates and Forecasts (2019-2030)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

3 CHECKPOINT INHIBITOR REFRACTORY CANCER MARKET COMPETITIVE LANDSCAPE

- 3.1 Global Checkpoint Inhibitor Refractory Cancer Sales by Manufacturers (2019-2024)
- 3.2 Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Checkpoint Inhibitor Refractory Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Checkpoint Inhibitor Refractory Cancer Average Price by Manufacturers (2019-2024)
- 3.5 Manufacturers Checkpoint Inhibitor Refractory Cancer Sales Sites, Area Served, Product Type
- 3.6 Checkpoint Inhibitor Refractory Cancer Market Competitive Situation and Trends
 - 3.6.1 Checkpoint Inhibitor Refractory Cancer Market Concentration Rate

3.6.2 Global 5 and 10 Largest Checkpoint Inhibitor Refractory Cancer Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 CHECKPOINT INHIBITOR REFRACTORY CANCER INDUSTRY CHAIN ANALYSIS

4.1 Checkpoint Inhibitor Refractory Cancer Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF CHECKPOINT INHIBITOR REFRACTORY CANCER MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

6 CHECKPOINT INHIBITOR REFRACTORY CANCER MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Checkpoint Inhibitor Refractory Cancer Sales Market Share by Type (2019-2024)

6.3 Global Checkpoint Inhibitor Refractory Cancer Market Size Market Share by Type (2019-2024)

6.4 Global Checkpoint Inhibitor Refractory Cancer Price by Type (2019-2024)

7 CHECKPOINT INHIBITOR REFRACTORY CANCER MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Checkpoint Inhibitor Refractory Cancer Market Sales by Application (2019-2024)

7.3 Global Checkpoint Inhibitor Refractory Cancer Market Size (M USD) by Application (2019-2024)

7.4 Global Checkpoint Inhibitor Refractory Cancer Sales Growth Rate by Application (2019-2024)

8 CHECKPOINT INHIBITOR REFRACTORY CANCER MARKET SEGMENTATION BY REGION

8.1 Global Checkpoint Inhibitor Refractory Cancer Sales by Region

8.1.1 Global Checkpoint Inhibitor Refractory Cancer Sales by Region

8.1.2 Global Checkpoint Inhibitor Refractory Cancer Sales Market Share by Region

8.2 North America

8.2.1 North America Checkpoint Inhibitor Refractory Cancer Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Checkpoint Inhibitor Refractory Cancer Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Checkpoint Inhibitor Refractory Cancer Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Checkpoint Inhibitor Refractory Cancer Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Checkpoint Inhibitor Refractory Cancer Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Bristol-Myers Squibb

9.1.1 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Basic Information

9.1.2 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product Overview

9.1.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product Market Performance

9.1.4 Bristol-Myers Squibb Business Overview

9.1.5 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer SWOT Analysis

9.1.6 Bristol-Myers Squibb Recent Developments

9.2 AstraZeneca

9.2.1 AstraZeneca Checkpoint Inhibitor Refractory Cancer Basic Information

9.2.2 AstraZeneca Checkpoint Inhibitor Refractory Cancer Product Overview

9.2.3 AstraZeneca Checkpoint Inhibitor Refractory Cancer Product Market Performance

9.2.4 AstraZeneca Business Overview

9.2.5 AstraZeneca Checkpoint Inhibitor Refractory Cancer SWOT Analysis

9.2.6 AstraZeneca Recent Developments

9.3 Merck

9.3.1 Merck Checkpoint Inhibitor Refractory Cancer Basic Information

9.3.2 Merck Checkpoint Inhibitor Refractory Cancer Product Overview

9.3.3 Merck Checkpoint Inhibitor Refractory Cancer Product Market Performance

9.3.4 Merck Checkpoint Inhibitor Refractory Cancer SWOT Analysis

9.3.5 Merck Business Overview

9.3.6 Merck Recent Developments

9.4 Roche

9.4.1 Roche Checkpoint Inhibitor Refractory Cancer Basic Information

9.4.2 Roche Checkpoint Inhibitor Refractory Cancer Product Overview

9.4.3 Roche Checkpoint Inhibitor Refractory Cancer Product Market Performance

9.4.4 Roche Business Overview

9.4.5 Roche Recent Developments

9.5 Regeneron Pharmaceuticals

9.5.1 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Basic

Information

9.5.2 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Product Overview

9.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Product Market Performance

9.5.4 Regeneron Pharmaceuticals Business Overview

9.5.5 Regeneron Pharmaceuticals Recent Developments

9.6 Bristol-Myers Squibb

9.6.1 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Basic Information

9.6.2 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product Overview

9.6.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product Market Performance

9.6.4 Bristol-Myers Squibb Business Overview

9.6.5 Bristol-Myers Squibb Recent Developments

9.7 Janssen Research and Development

9.7.1 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Basic Information

9.7.2 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Product Overview

9.7.3 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Product Market Performance

9.7.4 Janssen Research and Development Business Overview

9.7.5 Janssen Research and Development Recent Developments

9.8 4D pharma

9.8.1 4D pharma Checkpoint Inhibitor Refractory Cancer Basic Information

9.8.2 4D pharma Checkpoint Inhibitor Refractory Cancer Product Overview

9.8.3 4D pharma Checkpoint Inhibitor Refractory Cancer Product Market Performance

9.8.4 4D pharma Business Overview

9.8.5 4D pharma Recent Developments

9.9 4SC AG

9.9.1 4SC AG Checkpoint Inhibitor Refractory Cancer Basic Information

9.9.2 4SC AG Checkpoint Inhibitor Refractory Cancer Product Overview

9.9.3 4SC AG Checkpoint Inhibitor Refractory Cancer Product Market Performance

9.9.4 4SC AG Business Overview

9.9.5 4SC AG Recent Developments

9.10 OncoSec Medical

9.10.1 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Basic Information

9.10.2 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Product Overview

9.10.3 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Product Market

Performance

- 9.10.4 OncoSec Medical Business Overview
- 9.10.5 OncoSec Medical Recent Developments

9.11 Mirati Therapeutics

- 9.11.1 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Basic Information
- 9.11.2 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Product Overview
- 9.11.3 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Product Market

Performance

- 9.11.4 Mirati Therapeutics Business Overview
- 9.11.5 Mirati Therapeutics Recent Developments

9.12 Ascentage Pharma Group

- 9.12.1 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Basic Information
- 9.12.2 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Product Overview
- 9.12.3 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Product

Market Performance

- 9.12.4 Ascentage Pharma Group Business Overview
- 9.12.5 Ascentage Pharma Group Recent Developments

9.13 ENB Therapeutics

- 9.13.1 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Basic Information
- 9.13.2 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Product Overview
- 9.13.3 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Product Market

Performance

- 9.13.4 ENB Therapeutics Business Overview
- 9.13.5 ENB Therapeutics Recent Developments

9.14 Exicure

- 9.14.1 Exicure Checkpoint Inhibitor Refractory Cancer Basic Information
- 9.14.2 Exicure Checkpoint Inhibitor Refractory Cancer Product Overview
- 9.14.3 Exicure Checkpoint Inhibitor Refractory Cancer Product Market Performance
- 9.14.4 Exicure Business Overview
- 9.14.5 Exicure Recent Developments

9.15 Eisai

- 9.15.1 Eisai Checkpoint Inhibitor Refractory Cancer Basic Information
- 9.15.2 Eisai Checkpoint Inhibitor Refractory Cancer Product Overview
- 9.15.3 Eisai Checkpoint Inhibitor Refractory Cancer Product Market Performance
- 9.15.4 Eisai Business Overview
- 9.15.5 Eisai Recent Developments

9.16 Kartos Therapeutics

- 9.16.1 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Basic Information
- 9.16.2 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Product Overview
- 9.16.3 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Product Market Performance
- 9.16.4 Kartos Therapeutics Business Overview
- 9.16.5 Kartos Therapeutics Recent Developments
- 9.17 Exelixis
 - 9.17.1 Exelixis Checkpoint Inhibitor Refractory Cancer Basic Information
 - 9.17.2 Exelixis Checkpoint Inhibitor Refractory Cancer Product Overview
 - 9.17.3 Exelixis Checkpoint Inhibitor Refractory Cancer Product Market Performance
 - 9.17.4 Exelixis Business Overview
 - 9.17.5 Exelixis Recent Developments
- 9.18 ImmunityBio
 - 9.18.1 ImmunityBio Checkpoint Inhibitor Refractory Cancer Basic Information
 - 9.18.2 ImmunityBio Checkpoint Inhibitor Refractory Cancer Product Overview
 - 9.18.3 ImmunityBio Checkpoint Inhibitor Refractory Cancer Product Market Performance
 - 9.18.4 ImmunityBio Business Overview
 - 9.18.5 ImmunityBio Recent Developments

10 CHECKPOINT INHIBITOR REFRACTORY CANCER MARKET FORECAST BY REGION

- 10.1 Global Checkpoint Inhibitor Refractory Cancer Market Size Forecast
- 10.2 Global Checkpoint Inhibitor Refractory Cancer Market Forecast by Region
 - 10.2.1 North America Market Size Forecast by Country
 - 10.2.2 Europe Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Country
 - 10.2.3 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Region
 - 10.2.4 South America Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Country
 - 10.2.5 Middle East and Africa Forecasted Consumption of Checkpoint Inhibitor Refractory Cancer by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)

- 11.1 Global Checkpoint Inhibitor Refractory Cancer Market Forecast by Type (2025-2030)

11.1.1 Global Forecasted Sales of Checkpoint Inhibitor Refractory Cancer by Type (2025-2030)

11.1.2 Global Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Type (2025-2030)

11.1.3 Global Forecasted Price of Checkpoint Inhibitor Refractory Cancer by Type (2025-2030)

11.2 Global Checkpoint Inhibitor Refractory Cancer Market Forecast by Application (2025-2030)

11.2.1 Global Checkpoint Inhibitor Refractory Cancer Sales (K Units) Forecast by Application

11.2.2 Global Checkpoint Inhibitor Refractory Cancer Market Size (M USD) Forecast by Application (2025-2030)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Checkpoint Inhibitor Refractory Cancer Market Size Comparison by Region (M USD)

Table 5. Global Checkpoint Inhibitor Refractory Cancer Sales (K Units) by Manufacturers (2019-2024)

Table 6. Global Checkpoint Inhibitor Refractory Cancer Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Checkpoint Inhibitor Refractory Cancer Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Checkpoint Inhibitor Refractory Cancer Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitor Refractory Cancer as of 2022)

Table 10. Global Market Checkpoint Inhibitor Refractory Cancer Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Checkpoint Inhibitor Refractory Cancer Sales Sites and Area Served

Table 12. Manufacturers Checkpoint Inhibitor Refractory Cancer Product Type

Table 13. Global Checkpoint Inhibitor Refractory Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Checkpoint Inhibitor Refractory Cancer

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Checkpoint Inhibitor Refractory Cancer Market Challenges

Table 22. Global Checkpoint Inhibitor Refractory Cancer Sales by Type (K Units)

Table 23. Global Checkpoint Inhibitor Refractory Cancer Market Size by Type (M USD)

Table 24. Global Checkpoint Inhibitor Refractory Cancer Sales (K Units) by Type (2019-2024)

Table 25. Global Checkpoint Inhibitor Refractory Cancer Sales Market Share by Type

(2019-2024)

Table 26. Global Checkpoint Inhibitor Refractory Cancer Market Size (M USD) by Type (2019-2024)

Table 27. Global Checkpoint Inhibitor Refractory Cancer Market Size Share by Type (2019-2024)

Table 28. Global Checkpoint Inhibitor Refractory Cancer Price (USD/Unit) by Type (2019-2024)

Table 29. Global Checkpoint Inhibitor Refractory Cancer Sales (K Units) by Application

Table 30. Global Checkpoint Inhibitor Refractory Cancer Market Size by Application

Table 31. Global Checkpoint Inhibitor Refractory Cancer Sales by Application (2019-2024) & (K Units)

Table 32. Global Checkpoint Inhibitor Refractory Cancer Sales Market Share by Application (2019-2024)

Table 33. Global Checkpoint Inhibitor Refractory Cancer Sales by Application (2019-2024) & (M USD)

Table 34. Global Checkpoint Inhibitor Refractory Cancer Market Share by Application (2019-2024)

Table 35. Global Checkpoint Inhibitor Refractory Cancer Sales Growth Rate by Application (2019-2024)

Table 36. Global Checkpoint Inhibitor Refractory Cancer Sales by Region (2019-2024) & (K Units)

Table 37. Global Checkpoint Inhibitor Refractory Cancer Sales Market Share by Region (2019-2024)

Table 38. North America Checkpoint Inhibitor Refractory Cancer Sales by Country (2019-2024) & (K Units)

Table 39. Europe Checkpoint Inhibitor Refractory Cancer Sales by Country (2019-2024) & (K Units)

Table 40. Asia Pacific Checkpoint Inhibitor Refractory Cancer Sales by Region (2019-2024) & (K Units)

Table 41. South America Checkpoint Inhibitor Refractory Cancer Sales by Country (2019-2024) & (K Units)

Table 42. Middle East and Africa Checkpoint Inhibitor Refractory Cancer Sales by Region (2019-2024) & (K Units)

Table 43. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Basic Information

Table 44. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product Overview

Table 45. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

- Table 46. Bristol-Myers Squibb Business Overview
- Table 47. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer SWOT Analysis
- Table 48. Bristol-Myers Squibb Recent Developments
- Table 49. AstraZeneca Checkpoint Inhibitor Refractory Cancer Basic Information
- Table 50. AstraZeneca Checkpoint Inhibitor Refractory Cancer Product Overview
- Table 51. AstraZeneca Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 52. AstraZeneca Business Overview
- Table 53. AstraZeneca Checkpoint Inhibitor Refractory Cancer SWOT Analysis
- Table 54. AstraZeneca Recent Developments
- Table 55. Merck Checkpoint Inhibitor Refractory Cancer Basic Information
- Table 56. Merck Checkpoint Inhibitor Refractory Cancer Product Overview
- Table 57. Merck Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 58. Merck Checkpoint Inhibitor Refractory Cancer SWOT Analysis
- Table 59. Merck Business Overview
- Table 60. Merck Recent Developments
- Table 61. Roche Checkpoint Inhibitor Refractory Cancer Basic Information
- Table 62. Roche Checkpoint Inhibitor Refractory Cancer Product Overview
- Table 63. Roche Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 64. Roche Business Overview
- Table 65. Roche Recent Developments
- Table 66. Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Basic Information
- Table 67. Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Product Overview
- Table 68. Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 69. Regeneron Pharmaceuticals Business Overview
- Table 70. Regeneron Pharmaceuticals Recent Developments
- Table 71. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Basic Information
- Table 72. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product Overview
- Table 73. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 74. Bristol-Myers Squibb Business Overview
- Table 75. Bristol-Myers Squibb Recent Developments

Table 76. Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Basic Information

Table 77. Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Product Overview

Table 78. Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 79. Janssen Research and Development Business Overview

Table 80. Janssen Research and Development Recent Developments

Table 81. 4D pharma Checkpoint Inhibitor Refractory Cancer Basic Information

Table 82. 4D pharma Checkpoint Inhibitor Refractory Cancer Product Overview

Table 83. 4D pharma Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 84. 4D pharma Business Overview

Table 85. 4D pharma Recent Developments

Table 86. 4SC AG Checkpoint Inhibitor Refractory Cancer Basic Information

Table 87. 4SC AG Checkpoint Inhibitor Refractory Cancer Product Overview

Table 88. 4SC AG Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 89. 4SC AG Business Overview

Table 90. 4SC AG Recent Developments

Table 91. OncoSec Medical Checkpoint Inhibitor Refractory Cancer Basic Information

Table 92. OncoSec Medical Checkpoint Inhibitor Refractory Cancer Product Overview

Table 93. OncoSec Medical Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 94. OncoSec Medical Business Overview

Table 95. OncoSec Medical Recent Developments

Table 96. Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Basic Information

Table 97. Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Product Overview

Table 98. Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 99. Mirati Therapeutics Business Overview

Table 100. Mirati Therapeutics Recent Developments

Table 101. Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Basic Information

Table 102. Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Product Overview

Table 103. Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 104. Ascentage Pharma Group Business Overview

- Table 105. Ascentage Pharma Group Recent Developments
- Table 106. ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Basic Information
- Table 107. ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Product Overview
- Table 108. ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 109. ENB Therapeutics Business Overview
- Table 110. ENB Therapeutics Recent Developments
- Table 111. Exicure Checkpoint Inhibitor Refractory Cancer Basic Information
- Table 112. Exicure Checkpoint Inhibitor Refractory Cancer Product Overview
- Table 113. Exicure Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 114. Exicure Business Overview
- Table 115. Exicure Recent Developments
- Table 116. Eisai Checkpoint Inhibitor Refractory Cancer Basic Information
- Table 117. Eisai Checkpoint Inhibitor Refractory Cancer Product Overview
- Table 118. Eisai Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 119. Eisai Business Overview
- Table 120. Eisai Recent Developments
- Table 121. Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Basic Information
- Table 122. Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Product Overview
- Table 123. Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 124. Kartos Therapeutics Business Overview
- Table 125. Kartos Therapeutics Recent Developments
- Table 126. Exelixis Checkpoint Inhibitor Refractory Cancer Basic Information
- Table 127. Exelixis Checkpoint Inhibitor Refractory Cancer Product Overview
- Table 128. Exelixis Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 129. Exelixis Business Overview
- Table 130. Exelixis Recent Developments
- Table 131. ImmunityBio Checkpoint Inhibitor Refractory Cancer Basic Information
- Table 132. ImmunityBio Checkpoint Inhibitor Refractory Cancer Product Overview
- Table 133. ImmunityBio Checkpoint Inhibitor Refractory Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 134. ImmunityBio Business Overview
- Table 135. ImmunityBio Recent Developments

Table 136. Global Checkpoint Inhibitor Refractory Cancer Sales Forecast by Region (2025-2030) & (K Units)

Table 137. Global Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Region (2025-2030) & (M USD)

Table 138. North America Checkpoint Inhibitor Refractory Cancer Sales Forecast by Country (2025-2030) & (K Units)

Table 139. North America Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Country (2025-2030) & (M USD)

Table 140. Europe Checkpoint Inhibitor Refractory Cancer Sales Forecast by Country (2025-2030) & (K Units)

Table 141. Europe Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Country (2025-2030) & (M USD)

Table 142. Asia Pacific Checkpoint Inhibitor Refractory Cancer Sales Forecast by Region (2025-2030) & (K Units)

Table 143. Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Region (2025-2030) & (M USD)

Table 144. South America Checkpoint Inhibitor Refractory Cancer Sales Forecast by Country (2025-2030) & (K Units)

Table 145. South America Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Country (2025-2030) & (M USD)

Table 146. Middle East and Africa Checkpoint Inhibitor Refractory Cancer Consumption Forecast by Country (2025-2030) & (Units)

Table 147. Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Country (2025-2030) & (M USD)

Table 148. Global Checkpoint Inhibitor Refractory Cancer Sales Forecast by Type (2025-2030) & (K Units)

Table 149. Global Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Type (2025-2030) & (M USD)

Table 150. Global Checkpoint Inhibitor Refractory Cancer Price Forecast by Type (2025-2030) & (USD/Unit)

Table 151. Global Checkpoint Inhibitor Refractory Cancer Sales (K Units) Forecast by Application (2025-2030)

Table 152. Global Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Application (2025-2030) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Checkpoint Inhibitor Refractory Cancer
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Checkpoint Inhibitor Refractory Cancer Market Size (M USD), 2019-2030
- Figure 5. Global Checkpoint Inhibitor Refractory Cancer Market Size (M USD) (2019-2030)
- Figure 6. Global Checkpoint Inhibitor Refractory Cancer Sales (K Units) & (2019-2030)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Checkpoint Inhibitor Refractory Cancer Market Size by Country (M USD)
- Figure 11. Checkpoint Inhibitor Refractory Cancer Sales Share by Manufacturers in 2023
- Figure 12. Global Checkpoint Inhibitor Refractory Cancer Revenue Share by Manufacturers in 2023
- Figure 13. Checkpoint Inhibitor Refractory Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
- Figure 14. Global Market Checkpoint Inhibitor Refractory Cancer Average Price (USD/Unit) of Key Manufacturers in 2023
- Figure 15. The Global 5 and 10 Largest Players: Market Share by Checkpoint Inhibitor Refractory Cancer Revenue in 2023
- Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 17. Global Checkpoint Inhibitor Refractory Cancer Market Share by Type
- Figure 18. Sales Market Share of Checkpoint Inhibitor Refractory Cancer by Type (2019-2024)
- Figure 19. Sales Market Share of Checkpoint Inhibitor Refractory Cancer by Type in 2023
- Figure 20. Market Size Share of Checkpoint Inhibitor Refractory Cancer by Type (2019-2024)
- Figure 21. Market Size Market Share of Checkpoint Inhibitor Refractory Cancer by Type in 2023
- Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 23. Global Checkpoint Inhibitor Refractory Cancer Market Share by Application
- Figure 24. Global Checkpoint Inhibitor Refractory Cancer Sales Market Share by

Application (2019-2024)

Figure 25. Global Checkpoint Inhibitor Refractory Cancer Sales Market Share by Application in 2023

Figure 26. Global Checkpoint Inhibitor Refractory Cancer Market Share by Application (2019-2024)

Figure 27. Global Checkpoint Inhibitor Refractory Cancer Market Share by Application in 2023

Figure 28. Global Checkpoint Inhibitor Refractory Cancer Sales Growth Rate by Application (2019-2024)

Figure 29. Global Checkpoint Inhibitor Refractory Cancer Sales Market Share by Region (2019-2024)

Figure 30. North America Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Checkpoint Inhibitor Refractory Cancer Sales Market Share by Country in 2023

Figure 32. U.S. Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Checkpoint Inhibitor Refractory Cancer Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Checkpoint Inhibitor Refractory Cancer Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Checkpoint Inhibitor Refractory Cancer Sales Market Share by Country in 2023

Figure 37. Germany Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Checkpoint Inhibitor Refractory Cancer Sales Market Share by Region in 2023

Figure 44. China Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (K Units)

Figure 50. South America Checkpoint Inhibitor Refractory Cancer Sales Market Share by Country in 2023

Figure 51. Brazil Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Checkpoint Inhibitor Refractory Cancer Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Checkpoint Inhibitor Refractory Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Checkpoint Inhibitor Refractory Cancer Sales Forecast by Volume (2019-2030) & (K Units)

Figure 62. Global Checkpoint Inhibitor Refractory Cancer Market Size Forecast by Value (2019-2030) & (M USD)

Figure 63. Global Checkpoint Inhibitor Refractory Cancer Sales Market Share Forecast

by Type (2025-2030)

Figure 64. Global Checkpoint Inhibitor Refractory Cancer Market Share Forecast by Type (2025-2030)

Figure 65. Global Checkpoint Inhibitor Refractory Cancer Sales Forecast by Application (2025-2030)

Figure 66. Global Checkpoint Inhibitor Refractory Cancer Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Checkpoint Inhibitor Refractory Cancer Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/GCD243FFB0ABEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCD243FFB0ABEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

